Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team.
balloon pulmonary angioplasty
chronic thromboembolic pulmonary hypertension
multidisciplinary team
pulmonary endarterectomy
survival
Journal
Therapeutic advances in respiratory disease
ISSN: 1753-4666
Titre abrégé: Ther Adv Respir Dis
Pays: England
ID NLM: 101316317
Informations de publication
Date de publication:
Historique:
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
27
6
2020
Statut:
ppublish
Résumé
Chronic thromboembolic pulmonary hypertension (CTEPH) may be treated with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapy (MT). Assessment in a multidisciplinary team of experts (CTEPH team) is currently recommended for treatment decision making. The aim of the present study was to report the effects of such an interdisciplinary concept. A total of 160 patients were consulted by the CTEPH team between December 2015 and September 2018. Patient baseline characteristics, CTEPH team decisions and implementation rates of diagnostic and therapeutic procedures were analysed. Change in World Health Organization (WHO) functional class and survival rates were evaluated by treatment strategy. A total of 51 (32%) patients were assessed as operable and 109 (68%) were deemed inoperable. Thirty-one (61% of operable patients) underwent PEA. Patients treated with PEA, BPA(+MT) and MT alone were 50.9 ± 14.7, 62.9 ± 15.1 and 68.9 ± 12.7 years old, respectively. At the follow-up, PEA patients had the highest WHO functional class improvement. Patients treated with BPA(+MT) had significantly better survival than PEA ( The CTEPH team ensures that necessary diagnostic procedures are performed. A relatively low proportion of patients was assessed by the CTEPH team as operable and underwent surgery, which in survivors resulted in the best functional improvement. Although patients undergoing BPA(+MT) were older than patients treated with PEA, their survival was better than patients subjected to PEA or MT alone.
Sections du résumé
BACKGROUND
Chronic thromboembolic pulmonary hypertension (CTEPH) may be treated with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapy (MT). Assessment in a multidisciplinary team of experts (CTEPH team) is currently recommended for treatment decision making. The aim of the present study was to report the effects of such an interdisciplinary concept.
METHODS AND RESULTS
A total of 160 patients were consulted by the CTEPH team between December 2015 and September 2018. Patient baseline characteristics, CTEPH team decisions and implementation rates of diagnostic and therapeutic procedures were analysed. Change in World Health Organization (WHO) functional class and survival rates were evaluated by treatment strategy. A total of 51 (32%) patients were assessed as operable and 109 (68%) were deemed inoperable. Thirty-one (61% of operable patients) underwent PEA. Patients treated with PEA, BPA(+MT) and MT alone were 50.9 ± 14.7, 62.9 ± 15.1 and 68.9 ± 12.7 years old, respectively. At the follow-up, PEA patients had the highest WHO functional class improvement. Patients treated with BPA(+MT) had significantly better survival than PEA (
CONCLUSIONS
The CTEPH team ensures that necessary diagnostic procedures are performed. A relatively low proportion of patients was assessed by the CTEPH team as operable and underwent surgery, which in survivors resulted in the best functional improvement. Although patients undergoing BPA(+MT) were older than patients treated with PEA, their survival was better than patients subjected to PEA or MT alone.
Identifiants
pubmed: 31878837
doi: 10.1177/1753466619891529
pmc: PMC6935880
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1753466619891529Références
J Heart Lung Transplant. 2018 Sep;37(9):1102-1110
pubmed: 30037729
Circulation. 2016 Mar 1;133(9):859-71
pubmed: 26826181
N Engl J Med. 2013 Jul 25;369(4):319-29
pubmed: 23883377
Eur Respir J. 2009 Feb;33(2):332-8
pubmed: 18829679
Kardiol Pol. 2017;75(7):645-654
pubmed: 28553870
Lancet Respir Med. 2017 Oct;5(10):785-794
pubmed: 28919201
Kardiol Pol. 2015;73(1):63-8
pubmed: 25625343
Circ Cardiovasc Interv. 2012 Dec;5(6):748-55
pubmed: 23192917
J Thorac Cardiovasc Surg. 2011 Mar;141(3):702-10
pubmed: 21335128
Circulation. 2001 Jan 2;103(1):10-3
pubmed: 11136677
Ann Thorac Surg. 2003 Nov;76(5):1457-62; discussion 1462-4
pubmed: 14602267
J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34
pubmed: 19095129
Ann Thorac Surg. 1996 Nov;62(5):1255-9; discussion 1259-60
pubmed: 8893554
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):null
pubmed: 29101270
Circ J. 2017 Mar 24;81(4):552-557
pubmed: 28154291
Eur Respir J. 2017 Dec 7;50(6):
pubmed: 29217606
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Clin Appl Thromb Hemost. 2016 Jan;22(1):92-9
pubmed: 24875780
Int J Cardiol. 2019 Mar 1;278:232-237
pubmed: 30409735
Int J Cardiol. 2018 Oct 15;269:283-288
pubmed: 30017517
Circulation. 2014 Aug 5;130(6):508-18
pubmed: 25092279
Lancet Respir Med. 2019 Mar;7(3):239-248
pubmed: 30477763
Am J Respir Crit Care Med. 2011 Jun 15;183(12):1605-13
pubmed: 21330453
Circ J. 2018 Apr 25;82(5):1428-1436
pubmed: 29540628
Eur Respir Rev. 2017 Mar 29;26(143):
pubmed: 28356404
Am J Respir Crit Care Med. 2008 May 15;177(10):1122-7
pubmed: 18292468
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
Eur Respir J. 2015 May;45(5):1293-302
pubmed: 25395036
Ann Thorac Surg. 2012 Jul;94(1):97-103; discussion 103
pubmed: 22626752
Postepy Kardiol Interwencyjnej. 2017;13(2):180-181
pubmed: 28798794
Chest. 2008 Aug;134(2):229-236
pubmed: 18263674
EuroIntervention. 2018 Apr 20;13(17):2060-2068
pubmed: 28804055
J Heart Lung Transplant. 2016 May;35(5):591-6
pubmed: 26612053
Eur Respir Rev. 2017 Mar 15;26(143):
pubmed: 28298388
Heart Lung. 2019 Jan;48(1):28-33
pubmed: 30115494